US Congress House Bill 4913 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Introduced on October 30 2019 - 25% progression, died in committee
Action: 2019-10-30 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Establishes additional requirements for prescription drug plan (PDP) sponsors that use formularies under the Medicare prescription drug benefit. Specifically, the bill requires PDP formularies to include covered generic drugs and biosimilars for which the wholesale acquisition cost is less than that of the reference (i.e., brand-name) product. PDP sponsors must also establish specific cost-sharing tiers that apply lower cost-sharing requirements for such covered generic drugs and biosimilars as compared to those for brand-name products. The bill also prohibits PDP sponsors from instituting certain requirements relating to access to such covered generic drugs and biosimilars that are more restrictive than those for brand-name products (e.g., prior authorization requirements).

To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.

Rep. David McKinley [R-WV]	Rep. Ann Kuster [D-NH]	Sen. Peter Welch [D-VT]	Rep. Pete Olson [R-TX]
Sen. Ted Budd [R-NC]	Rep. Paul Tonko [D-NY]	Rep. David Joyce [R-OH]	Rep. Darren Soto [D-FL]
Rep. Earl Carter [R-GA]	Rep. Angela Craig [D-MN]	Rep. Karen Bass [D-CA]	Rep. Salud Carbajal [D-CA]
Rep. Guy Reschenthaler [R-PA]	Rep. Bobby Rush [D-IL]	Rep. Doris Matsui [D-CA]	Rep. Raul Ruiz [D-CA]
Rep. Anthony Gonzalez [R-OH]	Rep. John Garamendi [D-CA]	Rep. Alexander Mooney [R-WV]	Rep. Lance Gooden [R-TX]
Rep. Cathy McMorris Rodgers [R-WA]	Rep. Brenda Lawrence [D-MI]

Date	Chamber	Action
2019-10-30	House	Referred to the Subcommittee on Health.
2019-10-30	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-10-30	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-10-30	House	Introduced in House

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/house-bill/4913/all-info
Text	https://www.congress.gov/116/bills/hr4913/BILLS-116hr4913ih.pdf